Acclean Chlorhexidine Gluconate 0.12% Oral Rinse

Acclean Chlorhexidine Gluconate 0.12% Oral Rinse Manufacturers

• Henry Schein, Inc.
  

  ×

  Acclean Chlorhexidine Gluconate 0.12% Oral Rinse | Bioactive Nutritional, Inc.

  

  ---

  10 drops orally, 3 times a day. Consult a physician for use in children under 12 years of age.

  Close
  No Recall

  More Info
• Henry Schein, Inc.
  

  ×

  Acclean Chlorhexidine Gluconate 0.12% Oral Rinse | Paddock Laboratories, Llc

  

  ---

  2.1 Initial Dosing

  To avoid medication errors, prescribers and pharmacists must be aware that hydromorphone is available as both immediate-release 8 mg tablets and extended-release 8 mg tablets.

  Hydromorphone hydrochloride extended release tablets should be prescribed only by healthcare professionals who are knowledgeable in the use of potent opioids for the management of chronic pain.

  Due to the risk of respiratory depression, hydromorphone hydrochloride extended release tablets are only indicated for use in patients who are already opioid-tolerant. Discontinue or taper all other extended-release opioids when beginning hydromorphone hydrochloride extended release tablets therapy. As hydromorphone hydrochloride extended release tablets are only for use in opioid-tolerant patients, do not begin any patient on hydromorphone hydrochloride extended release tablets as the first opioid.

  Patients considered opioid-tolerant are those who are taking at least 60 mg of morphine daily, or at least 30 mg of oral oxycodone daily, or at least 8 mg of oral hydromorphone daily or an equianalgesic dose of another opioid for a week or longer.

  Initiate the dosing regimen for each patient individually, taking into account the patient's prior analgesic treatment experience and risk factors for addiction, abuse, and misuse [see Warnings and Precautions (5.1)]. Monitor patients closely for respiratory depression, especially within the first 24 to 72 hours of initiating therapy with hydromorphone hydrochloride extended release tablets [see Warnings and Precautions (5.2)].

  Hydromorphone hydrochloride extended release tablets must be taken whole. Crushing, chewing, or dissolving hydromorphone hydrochloride extended release tablets will result in uncontrolled delivery of hydromorphone and can lead to overdose or death [see Warnings and Precautions (5.2)].

  Conversion from Other Oral Hydromorphone Formulations to Hydromorphone Hydrochloride Extended Release Tablets

  Patients receiving oral immediate-release hydromorphone may be converted to hydromorphone hydrochloride extended release tablets by administering a starting dose equivalent to the patient’s total daily oral hydromorphone dose, taken once daily.

  Conversion from Other Oral Opioids to Hydromorphone Hydrochloride Extended Release Tablets

  Discontinue all other around-the-clock opioid drugs when hydromorphone hydrochloride extended release tablets therapy is initiated.

  While there are useful tables of opioid equivalents readily available, there is substantial inter-patient variability in the relative potency of different opioid drugs and products. As such, it is safer to underestimate a patient’s 24-hour oral hydromorphone requirements and provide rescue medication (e.g., immediate-release opioid) than to overestimate the 24-hour oral hydromorphone requirements, which could result in adverse reactions.

  In a hydromorphone hydrochloride extended release tablets clinical trial with an open-label titration period, patients were converted from their prior opioid to hydromorphone hydrochloride extended release tablets using the Table 1 as a guide for the initial hydromorphone hydrochloride extended release tablets dose. The recommended starting dose of hydromorphone hydrochloride extended release tablets is 50% of the calculated estimate of daily hydromorphone requirement. Calculate the estimated daily hydromorphone requirement using Table 1.

  Consider the following when using the information in Table 1:

  • This is not a table of equianalgesic doses. • The conversion factors in this table are only for the conversion from one of the listed oral opioid analgesics to hydromorphone hydrochloride extended release tablets. • The table cannot be used to convert from hydromorphone hydrochloride extended release tablets to another opioid. Doing so will result in an overestimation of the dose of the new opioid and may result in fatal overdose.

  To calculate the estimated hydromorphone hydrochloride extended release tablets dose using Table 1:

  • For patients on a single opioid, sum the current total daily dose of the opioid and then multiply the total daily dose by the conversion factor to calculate the approximate oral hydromorphone daily dose. • For patients on a regimen of more than one opioid, calculate the approximate oral hydromorphone dose for each opioid and sum the totals to obtain the approximate total hydromorphone daily dose. • For patients on a regimen of fixed-ratio opioid/non-opioid analgesic products, use only the opioid component of these products in the conversion.

  Always round the dose down, if necessary, to the appropriate hydromorphone hydrochloride extended release tablets strength(s) available.

  Example conversion from a single opioid to hydromorphone hydrochloride extended release tablets:

  Step 1: Sum the total daily dose of the opioid

  • 30 mg of oxycodone 2 times daily = 60 mg total daily dose of oxycodone

  Step 2: Calculate the approximate equivalent dose of oral hydromorphone based on the total daily dose of the current opioid using Table 1

  • 60 mg total daily dose of oxycodone x Conversion Factor of 0.4 = 24 mg of oral hydromorphone daily

  Step 3: Calculate the approximate starting dose of hydromorphone hydrochloride extended release tablets to be given every 24 hours, which is 50% of the calculated oral hydromorphone dose. Round down, if necessary, to the appropriate hydromorphone hydrochloride extended release tablet strengths available.

  • 50% of 24 mg results in an initial dose of 12 mg of hydromorphone hydrochloride extended release tablets once daily • Adjust individually for each patient

  Close observation and frequent titration are warranted until pain management is stable on the new opioid. Monitor patients for signs and symptoms of opioid withdrawal or for signs of over-sedation/toxicity after converting patients to hydromorphone hydrochloride extended release tablets.

  Conversion from Transdermal Fentanyl to Hydromorphone Hydrochloride Extended Release Tablets

  Eighteen hours following the removal of the transdermal fentanyl patch, hydromorphone hydrochloride extended release tablets treatment can be initiated. To calculate the 24-hour hydromorphone hydrochloride extended release tablets dose, use a conversion factor of 25 mcg/hr fentanyl transdermal patch to 12 mg of hydromorphone hydrochloride extended release tablets. Then reduce the hydromorphone hydrochloride extended release tablets dose by 50%.

  For example:

  Step 1: Identify the dose of transdermal fentanyl.

  • 75 mg of transdermal fentanyl

  Step 2: Use the conversion factor of 25 mcg/hr fentanyl transdermal patch to 12 mg of hydromorphone hydrochloride extended release tablets.

  • 75 mg of transdermal fentanyl : 36 mg total daily dose of hydromorphone hydrochloride extended release tablets

  Step 3: Calculate the approximate starting dose of hydromorphone hydrochloride extended release tablets to be given every 24 hours, which is 50% of the converted dose. Round down, if necessary, to the appropriate hydromorphone hydrochloride extended release tablet strengths available.

  • 50% of 36 mg results in an initial dose of 18 mg, which would be rounded down to 16 mg of hydromorphone hydrochloride extended release tablets once daily • Adjust individually for each patient

  Conversion from Methadone to Hydromorphone Hydrochloride Extended Release Tablets

  Close monitoring is of particular importance when converting from methadone to other opioid agonists. The ratio between methadone and other opioid agonists may vary widely as a function of previous dose exposure. Methadone has a long half-life and can accumulate in the plasma.

  2.2 Titration and Maintenance of Therapy

  Individually titrate hydromorphone hydrochloride extended release tablets to a dose that provides adequate analgesia and minimizes adverse reactions. Continually reevaluate patients receiving hydromorphone hydrochloride extended release tablets to assess the maintenance of pain control and the relative incidence of adverse reactions, as well as monitoring for the development of addiction, abuse, or misuse. Frequent communication is important among the prescriber, other members of the healthcare team, the patient, and the caregiver/family during periods of changing analgesic requirements, including initial titration. During chronic therapy, periodically reassess the continued need for opioid analgesics.

  Plasma levels of hydromorphone hydrochloride extended release tablets are sustained for 18 to 24 hours. Dosage adjustments of hydromorphone hydrochloride extended release tablets may be made in increments of 4 to 8 mg every 3 to 4 days as needed to achieve adequate analgesia.

  Patients who experience breakthrough pain may require a dose increase of hydromorphone hydrochloride extended release tablets, or may need rescue medication with an appropriate dose of an immediate-release analgesic. If the level of pain increases after dose stabilization, attempt to identify the source of increased pain before increasing the hydromorphone hydrochloride extended release tablets dose.

  If unacceptable opioid-related adverse reactions are observed, the subsequent doses may be reduced. Adjust the dose to obtain an appropriate balance between management of pain and opioid-related adverse reactions.

  2.3 Discontinuation of Hydromorphone Hydrochloride Extended Release Tablets

  When a patient no longer requires therapy with hydromorphone hydrochloride extended release tablets, taper doses gradually, by 25% to 50% every 2 or 3 days down to a dose of 8 mg before discontinuation of therapy, to prevent signs and symptoms of withdrawal in the opioid-tolerant patient.

  To dispose of unused hydromorphone hydrochloride extended release tablets flush all remaining tablets down the toilet or remit to authorities at a certified drug take-back program.

  2.4 Hepatic Impairment

  Start patients with moderate hepatic impairment on 25% of the hydromorphone hydrochloride extended release tablets dose that would be prescribed for patients with normal hepatic function. Closely monitor patients with moderate hepatic impairment for respiratory and central nervous system depression during initiation of therapy with hydromorphone hydrochloride extended release tablets and during dose titration. Use of alternate analgesics is recommended for patients with severe hepatic impairment [see Use in Specific Populations (8.6)].

  2.5 Renal Impairment

  Start patients with moderate renal impairment on 50% and patients with severe renal impairment on 25% of the hydromorphone hydrochloride extended release tablets dose that would be prescribed for patients with normal renal function. Closely monitor patients with renal impairment for respiratory and central nervous system depression during initiation of therapy with hydromorphone hydrochloride extended release tablets and during dose titration. As hydromorphone hydrochloride extended release tablets are only intended for once daily administration, consider use of an alternate analgesic that may permit more flexibility with the dosing interval in patients with severe renal impairment [see Use in Specific Populations (8.7)].

  2.6 Administration of Hydromorphone Hydrochloride Extended Release Tablets

  Instruct patients to swallow hydromorphone hydrochloride extended release tablets intact. The tablets are not to be crushed, dissolved, or chewed due to the risk of rapid release and absorption of a potentially fatal dose of hydromorphone [see Warnings and Precautions (5.2)].

  Close
  No Recall

  More Info